(202 days)
Not Found
No
The document describes a digital ophthalmic imaging system and a modification to its light source. It mentions image capture, storage, viewing, retrieval, and export, but there is no mention of AI, ML, or any form of automated image analysis or interpretation using such technologies. The performance study focuses on the accuracy of human graders interpreting the images compared to a reference standard.
No
The device is described as an "Ophthalmic Imaging System" used for general ophthalmic imaging, photodocumentation, and screening for retinopathy. Its primary function is to capture and store images, which are diagnostic purposes rather than therapeutic.
Yes
The device is indicated for "Screening for Type 2 pre-threshold retinopathy of prematurity (ROP) or treatment-requiring ROP," which involves identifying a disease state, making it a diagnostic device.
No
The device description clearly outlines multiple hardware components including a digital camera in a handpiece, lenses, an on-board computer, a light source (Halogen and optional LED), a footswitch, a keyboard, and a console monitor. While it includes proprietary software, it is an integral part of a larger hardware system.
Based on the provided information, this device is not an In Vitro Diagnostic (IVD).
Here's why:
- IVDs analyze samples taken from the human body. The device description clearly states that the RetCam 3 Ophthalmic Imaging System captures images of the eye (retinal, corneal, external). It does not analyze blood, tissue, or other biological samples.
- The intended use is imaging and photodocumentation. The primary function is to capture visual information of the eye for diagnosis and monitoring, not to perform tests on biological specimens.
- The device description focuses on imaging technology. The components described (digital camera, lenses, light sources, computer, software) are all related to capturing and managing images.
Therefore, the RetCam 3 Ophthalmic Imaging System, as described, falls under the category of a medical imaging device, not an In Vitro Diagnostic.
N/A
Intended Use / Indications for Use
- General ophthalmic imaging including retinal, corneal, and external imaging. .
- Photodocumentation of pediatric ocular diseases including retinopathy of prematurity (ROP). ♥
- Screening for Type 2 pre-threshold retinopathy of prematurity (ROP) (zone 1, stage 1 or 2, . without plus disease, or zone 2, stage 3, without plus disease) or treatment-requiring ROP, defined as Type 1 ROP (zone 1, any stage, with plus disease; zone 1, stage 3 without plus disease; or Zone 2, stage 2 or 3, with plus disease) or threshold ROP (at least 5 contiguous or 8 non-contiguous clock hours of stage 3 in zone 1 or 2, with plus disease)* in 35-37 week postmenstrual infants.
Product codes
HKI
Device Description
The RetCam 3 Ophthalmic Imaging System utilizes a digital camera in a handpiece with multiple field of view lenses to capture color ophthalmic digital images including retinal, corneal, and external images. An on board computer is used to store, view, retrieve, and export the digital ophthalmic images. A standard Halogen light source is used to provide illumination to the eye through the handpiece. An optional Xenon light source is also available with the RetCam 3 to facilitate imaging with fluorescein angiography. Light intensity, camera focus, and image capture are controlled by the use of a RetCam 3 footswitch and can also be controlled by a keyboard on the RetCam 3 consoles. A console monitor is provided with the RetCam 3 for viewing images. Proprietary software is installed in the computer to capture, store, view, retrieve, and export ophthalmic images.
A device modification to the RetCam 3 is being made to replace the Xenon light source module with an LED light source module. Third party testing has been performed and formal certification has been obtained verifying compliance with the applicable IEC 60601 electrical safety and electromagnetic compatibility standards. Bench testing has verified comparable safe maximum light irradiance output of the Xenon and LED light source modules. Bench testing has verified comparable fluoresce dye responses to the Xenon and LED light sources.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
digital camera
Anatomical Site
retinal, corneal, and external images of the eye
Indicated Patient Age Range
35-37 week postmenstrual infants.
Intended User / Care Setting
Trained neonatal nurses, NICU nurses
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Eyes from 67 consecutive infants underwent RetCam wide-field digital retinal imaging by trained neonatal nurses using a standard protocol of 3 images per eye and the 130 degree lens. The infants were 31 to 33 weeks and/or 35 to 37 weeks postmenstrual age (PMA).
Images were interpreted by three expert retinal specialist graders who provided a diagnosis and evaluation of image quality. Findings were compared with a reference standard of binocular indirect ophthalmoscopy (BIO) by experienced pediatric ophthalmologists. The target condition (referral warranted disease-the presence of Type 2 pre-threshold or worse ROP) in this study that supports the use of RetCam as an ROP screening tool is Type 2 Pre-threshold ROP (Zone 1, Stage 1 or 2, without plus disease, or Zone 2, Stage 3, without plus disease) or treatment requiring ROP (Zone 1, any stage, with Plus disease; Zone 1, stage 3 without plus disease; or Zone 2, stage 2 or 3 with Plus disease) or threshold ROP (at least 5 contiguous or 8 non-contiguous clock hours of stage 3 in zone 1 or 2, with plus disease) at 35-37 weeks PMA.
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Prospective trial, 67 infants.
Performance For Type 2 Threshold ROP Or Worse:
Grader A: Sensitivity 1.0 (26/26), Specificity 0.883 (83/94)
Grader B: Sensitivity 1.0 (26/26), Specificity 0.851 (80/94)
Grader C: Sensitivity 1.0 (26/26), Specificity 0.851 (80/94)
The 3 retinal specialist graders assessed the technical quality of the images for "adequate", "possibly adequate" or "inadequate". Each of them found that images taken at 35-37 weeks PMA by trained NICU nurses were technically "adequate" or "possibly adequate" at a rate of 93.3% to 100%.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Sensitivity, Specificity
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 886.1120 Ophthalmic camera.
(a)
Identification. An ophthalmic camera is an AC-powered device intended to take photographs of the eye and the surrounding area.(b)
Classification. Class II (special controls). The device, when it is a photorefractor or a general-use ophthalmic camera, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 886.9.
0
| 510(K) Summary
| K102859 | CLARITY MEDICAL SYSTEMS, INC. |
|---|---|
| Regulatory Authority: | Safe Medical Devices Act of 1990, 21 CFR 807.92 |
| Device Name: | RetCam 3 Ophthalmic Imaging System |
| Common Name(s): | Ophthalmic Imaging System |
| Classification Name(s): | Ophthalmic Camera |
| Manufacturer: | Clarity Medical Systems, Inc. |
| Reg. Number: | 2952489 |
| Address: | 5775 W. Las Positas Blvd. |
| Pleasanton, CA 94588-4084 | |
| Telephone: | (925) 463-7984 |
| Classification(s): | |
| Device Class: | Class II |
| Classification Panel: | Ophthalmology |
| Product Code(s): | HKI |
| Equivalent Predicate | |
| Device: | RetCam 3 Ophthalmic Imaging System, K090326, K081858 |
| RetCam II Ophthalmic Imaging System, K090326, K081858 |
Device Description:
The RetCam 3 Ophthalmic Imaging System utilizes a digital camera in a handpiece with multiple field of view lenses to capture color ophthalmic digital images including retinal, corneal, and external images. An on board computer is used to store, view, retrieve, and export the digital ophthalmic images. A standard Halogen light source is used to provide illumination to the eye through the handpiece. An optional Xenon light source is also available with the RetCam 3 to facilitate imaging with fluorescein angiography. Light intensity, camera focus, and image capture are controlled by the use of a RetCam 3 footswitch and can also be controlled by a keyboard on the RetCam 3 consoles. A console monitor is provided with the RetCam 3 for viewing images. Proprietary software is installed in the computer to capture, store, view, retrieve, and export ophthalmic images.
A device modification to the RetCam 3 is being made to replace the Xenon light source module with an LED light source module. Third party testing has been performed and formal certification has been obtained verifying compliance with the applicable IEC 60601 electrical safety and electromagnetic compatibility standards. Bench testing has verified comparable safe maximum light irradiance output of the Xenon and LED light source modules. Bench testing has verified comparable fluoresce dye responses to the Xenon and LED light sources.
1
Image /page/1/Picture/0 description: The image shows a handwritten sequence of characters inside of an oval shape. The characters are 'K102859'. The oval shape is drawn with a black line and appears to be hand-drawn as well.
Indication for Use:
- General ophthalmic imaging including retinal, corneal, and external imaging. .
- Photodocumentation of pediatric ocular diseases including retinopathy of prematurity (ROP). ♥
- Screening for Type 2 pre-threshold retinopathy of prematurity (ROP) (zone 1, stage 1 or 2, . without plus disease, or zone 2, stage 3, without plus disease) or treatment-requiring ROP, defined as Type 1 ROP (zone 1, any stage, with plus disease; zone 1, stage 3 without plus disease; or zone 2, stage 2 or 3, with plus disease) or threshold ROP (at least 5 contiguous or 8 non-contiguous clock hours of stage 3 in zone 1 or 2, with plus disease)* in 35-37 week postmenstrual infants.
*References:
-
- Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity: preliminary results. Archives of Ophthalmology 1988; 106(4):471-479.
-
- Early Treatment for Retinopathy of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the Early Treatment for Retinopathy of Prematurity Randomized Trial. Archives of Ophthalmology 2003; 121(12):1684-1694.
Clinical Performance Data:
Chiang, et. al. (Telemedical Retinopathy of Prematurity Diagnosis Accuracy and, Reliability, and Image Quality; Archives of Ophthalmology; 2007;125(11):1531-1538) reported the results of a prospective trial to measure the accuracy, reliability, and image quality of RetCam wide-field digital images to screen for ROP. Eyes from 67 consecutive infants underwent RetCam wide-field digital retinal imaging by trained neonatal nurses using a standard protocol of 3 images per eye and the 130 degree lens. The infants were 31 to 33 weeks and/or 35 to 37 weeks postmenstrual age (PMA).
Images were interpreted by three expert retinal specialist graders who provided a diagnosis and evaluation of image quality. Findings were compared with a reference standard of binocular indirect ophthalmoscopy (BIO) by experienced pediatric ophthalmologists. The target condition (referral warranted disease-the presence of Type 2 pre-threshold or worse ROP) in this study that supports the use of RetCam as an ROP screening tool is Type 2 Pre-threshold ROP (Zone 1, Stage 1 or 2, without plus disease, or Zone 2, Stage 3, without plus disease) or treatment requiring ROP (Zone 1, any stage, with Plus disease; Zone 1, stage 3 without plus disease; or Zone 2, stage 2 or 3 with Plus disease) or threshold ROP (at least 5 contiguous or 8 non-contiguous clock hours of stage 3 in zone 1 or 2, with plus disease) at 35-37 weeks PMA.
| Performance For Type 2 Threshold ROP Or Worse | ||||
|---|---|---|---|---|
| Grader | Sensitivity | ~95% CI for | ||
| Sensitivity | Specificity | ~95% CI for | ||
| Specificity | ||||
| A | 1.0 (26/26) | (0.868, 1.0) | 0.883 (83/94) | (0.802, 0.933) |
| B | 1.0 (26/26) | (0.868, 1.0) | 0.851 (80/94) | (0.765, 0.909) |
| C | 1.0 (26/26) | (0.868, 1.0) | 0.851 (80/94) | (0.765, 0.909) |
Sensitivity and Specificity Statistics by Grader
2
Image /page/2/Picture/0 description: The image shows a hand-drawn oval shape with the text "K102859" written inside. The text appears to be handwritten and slightly uneven. The oval shape is also not perfectly symmetrical, giving the image a casual, hand-drawn appearance.
Image Quality
Before providing a diagnosis for each image set, the 3 retinal specialist graders assessed the technical quality of the images for "adequate", "possibly adequate" or "inadequate". Each of them found that images taken at 35-37 weeks PMA by trained NICU nurses were technically "adequate" or "possibly adequate" at a rate of 93.3% to 100%.
Animal Studies
Image results were obtained using an approved LyChron non-clinical study protocol. The stated purpose of the protocol was to provide a controlled image comparison of both the Xenon and LED FA light sources in the same animal model. The images obtained with the LED FA light source are substantially equivalent in contrast and detail to images obtained using the Xenon FA module.
Bench Testing
IEC 60601-1 electrical safety testing, IEC 60601-1-2 EMC testing, and maximum light irradiance testing were conducted in accordance with established protocols. All testing demonstrated compliance with necessary electrical, EMC, and light safety requirements.
Conclusion
There are slight differences between the Xenon and LED generated light sources worth noting;
- FA light source Light output at the handpiece is in the same wavelength. . Though the values not are identical they have no adverse safety impact.
- FA Light Irradiance Irradiance levels also not identical but both Xenon and the . new LED light source meet ACIGH TLV specifications and have no adverse safety impact.
- FA Module software The LED FA light source has added software controls to . hardware controls whereas the Xenon based light source required no software. Accordingly, all appropriate V&V activities are complete. Safety has been demonstrated as not adversely impacted.
The Clinical Performance data note above was gathered using the RetCam II Ophthalmic Imaging System and supports the Indication for Use for both the RetCam II Ophthalmic Imaging System and the RetCam 3 Ophthalmic Imaging System as cleared in K090326.
Company Contact:
Gary A. Seeger Vice President, Quality Assurance and Regulatory Affairs Clarity Medical Systems, Inc.
3
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized eagle or bird symbol with three curved lines representing its wings. The bird is positioned to the right of a circular arrangement of text that reads "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA".
Food and Drug Administration 10903 New Hampshire Avenue Document Control Room -WO66-G609 Silver Spring, MD 20993-0002
Clarity Medical Systems, Inc. c/o Gary A. Seeger Vice President, Quality Assurance and Regulatory Affairs 5775 West Las Positas Blvd. St. 200 Pleasanton, CA 94588
Re: K102859
Trade/Device Name: RetCam3 Ophthalmic Imaging System Regulation Number: 21 CFR 886.1120 Regulation Name: Ophthalmic camera Regulatory Class: Class II Product Code: HKI Dated: March 15, 2011 Received: March 16, 2011
. APR 2 0 2011
Dear Mr. Seeger:
We have reviewed your Section 510(k) premarket notification of intent to market the devicereferenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic
4
product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer. Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.
Sincerely yours,
Kesia Alexander
for
Malvina B. Eydelman, M.D. Director Division of Ophthalmic, Neurological, and Ear, Nose and Throat Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
5
Page 1 of 1
510(k) Number:
RetCam3 Ophthalmic Imaging System Device Name(s):
Indications for Use Statement(s) for each and all above listed RetCam Systems:
- General ophthalmic imaging including retinal, corneal, and external imaging; .
- Photodocumentation of pediatric ocular diseases including retinopathy of prematurity . (ROP).
- · Screening for Type 2 pre-threshold retinopathy of prematurity (ROP) (zone 1, stage 1 or 2, without plus disease, or zone 2, stage 3, without plus disease) or treatment-requiring ROP, defined as Type 1 ROP (zone 1, any stage, with plus disease; zone 1, stage 3 without plus disease; or zone 2, stage 2 or 3, with plus disease) or threshold ROP (at least 5 contiguous or 8 non-contiguous clock hours of stage 3 in zone 1 or 2, with plus disease)* in 35-37 week postmenstrual infants.
*References:
-
- Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity: preliminary results. Archives of Ophthalmology 1988; 106{4):471-479.
-
- Early Treatment for Retinopathy of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the Early Treatment for Retinopathy of Prematurity Randomized Trial. Archives of Ophthalmology 2003; 121(12):1684-1694.
× Over the Counter Use . Prescription Use or
PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NECESSARY
Concurrence of CDRH, Office of Device Evaluation (ODE)
(Per 21 CFR 801.109)
Aesu.
(Division Sign-Off) Division of Ophthalmic, Neurological and Ear, Nose and Throat Devices
510(k) Number K102859